ArticleAmerican journal of translational research2018
BRAF mutation in papillary thyroid carcinoma (PTC) and its association with clinicopathological features and systemic inflammation response index (SIRI).
Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Prognostic associations of systemic inflammation response index (SIRI) in patients with head and neck cancer: a systematic review and meta-analysis.Oral oncology · 2026Pooled it
- The prognostic predictive value of systemic immune index and systemic inflammatory response index in nasopharyngeal carcinoma: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- An integrated multiomics-based risk model for predicting the prognosis and immune microenvironment status in patients with papillary thyroid carcinoma.Gland surgery · 2026Article
- Systemic inflammatory indices comprising monocytes provide a clinical significance for thyroid cancer identification.Scientific reports · 2025Article
- Deciphering the efficiency of preoperative systemic-immune inflammation related markers in predicting oncological outcomes of upper tract urothelial carcinoma patients after radical nephroureterectomy.Investigative and clinical urology · 2025Article
- Predictive Value of Inflammation Markers for Frailty in Older Patients with CVD.Clinical interventions in aging · 2025Article
- Assessing the Role of Inflammatory Markers in Predicting Central Lymph Node Metastasis in Papillary Thyroid Carcinoma.Iranian journal of otorhinolaryngology · 2025Article
- Evaluating the Role of CBC-Derived Indices in Children with Hashimoto's Thyroiditis.Diagnostics (Basel, Switzerland) · 2024Article
- Correlation between gene mutations and clinical characteristics in papillary thyroid cancer: a retrospective analysis of BRAF mutations and RET rearrangements.Thyroid research · 2024Article
- The Association of Pretreatment Systemic Immune Inflammatory Response Index (SII) and Neutrophil-to-Lymphocyte Ratio (NLR) with Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma.International journal of general medicine · 2024Article
- Developing Models to PredictBiomedicines · 2023Article
- The Accurate Interpretation and Clinical Significance of Morphological Features of Fine Needle Aspiration Cells in Papillary Thyroid Carcinoma.Analytical cellular pathology (Amsterdam) · 2023Article
- A novel proportional index to differentiate between demographically and clinically matched cases with papillary thyroid carcinoma or non-cancerous nodule: PLR-to-PDW ratio.American journal of translational research · 2023Article
- Profile ofThe application of clinical genetics · 2023Article
- AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour.World journal of surgical oncology · 2022Article
- Prognostic value of the systemic inflammation response index in patients with acute ischemic stroke.Brain and behavior · 2022Article
- The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study.Frontiers in molecular biosciences · 2022Article
- Synchronous Occurrence of Papillary Thyroid Carcinoma and Medullary Carcinoma in the Setting of Hashimoto's Thyroiditis and Multi Nodular Goiter.Iranian journal of pathology · 2022Article
- Monocyte to high-density lipoprotein cholesterol ratio as an independent risk factor for papillary thyroid carcinoma.Journal of clinical laboratory analysis · 2021Article
- LEM domain containing 1 promotes thyroid cancer cell proliferation and migration by activating the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition.Oncology letters · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present research was to investigate the association between the BRAF mutation and papillary thyroid carcinoma (PTC), and further explore the relationship between the systemic inflammation response index (SIRI) and BRAF mutation in patients with PTC. The clinicopathological data were extracted from the patients' medical records from June 2012 to June 2014 in our hospital. We enrolled 95 patients with PTC that have received the total or near-total thyroidectomy and pretracheal and paratracheal lymph node dissection. The blood samples were obtained before surgery. According to the BRAF mutation analysis, the patients were divided into two groups: BRAF mutation positive group and BRAF mutation negative group. The receiver operating characteristic curve (ROC) for the presence of BRAF mutation was used to evaluate the optimal cutoff value of SIRI. The ratio closest to the point with maximum sensitivity and specificity was defined as the optimal cutoff value. Univariate and multivariate logistic regression model were used to confirm the independent factors and compare observed and predicted outcomes. The BRAF mutation rates were 62.1% (59/95). The results indicated that BRAF mutation was significantly correlated with pathological TNM stage, monocyte, SIRI and Galectin-3. The pathological TNM stage, monocyte, SIRI and Galectin-3 were the significant risk factors associated with the presence of BRAF mutation. Moreover, we found that patients with low SIRI had higher BRAF mutation percentage than those with high SIRI, and patients with low monocyte had higher percentage than those with high monocyte. BRAF mutation is associated with the pathological TNM stage, monocyte, SIRI and Galectin-3, and SIRI was the significant risk factor with the BRAF mutation and patients with low SIRI have higher BRAF mutation.
Indexed as
Identifiers
30210710PMC6129531W2981912993What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.